Imprivata Patient Privacy Intelligence vs Protenus
The two AI centrality leaders in privacy monitoring, and they disagree at the root about how to find a violation. Imprivata explains: it tries first to tie each access to a legitimate clinical reason, an appointment, an encounter, a diagnosis code, and flags only the residue it cannot account for, which is a claim about evidence rather than about the person and earns the best governance grade among the workforce surveillance vendors, backed by the only peer reviewed validation in the category. Protenus profiles: it builds behavioural profiles of patients and users and reasons about whether an access was appropriate, an approach graded C on governance for flagging named clinicians with no published fairness evaluation, but it does what Imprivata does not, covering diversion as well as privacy from one platform with Best in KLAS in both. Imprivata's evidence largely predates its FairWarning and Maize merger, a continuity question to press. If your failure mode is minimising false accusations, start with Imprivata. If your failure mode is covering privacy and diversion together, start with Protenus.
- A method that structurally avoids flagging people for being unusual, graded A on governance, the best among the workforce surveillance vendors indexed: it explains each access against a legitimate clinical reason and surfaces only the residue it cannot account for, a claim about evidence rather than about the person.
- The only peer reviewed academic validation of a core method in the category, graded A on evidence: the Explanation Based Auditing research reported explanations for over 94 percent of accesses against a real health system log, with the work cited more than 50 times, plus Best in KLAS in 2021.
- Data does not leave the organisation, graded A on deployment and PHI: the system runs in a virtual machine inside the customer environment, and the vendor tells customers to keep manual review running until they have validated it themselves, the most conservative oversight posture in the lane.
- Two risk domains from one platform: patient privacy monitoring and drug diversion surveillance share one engine, so a single purchase covers both the privacy office and the pharmacy, where Imprivata is privacy only.
- Independent validation in both domains, graded B on evidence: Best in KLAS in 2023 for both patient privacy monitoring and drug diversion surveillance, which Imprivata's privacy only scope cannot match on breadth.
- The clearest AI necessity case, graded A on AI centrality: 100 percent coverage of accesses and medication transactions in place of manual sampling, with the same platform trained differently for the two use cases, protected by granted patents.
Side-by-Side
| Axis | I Imprivata Patient Privacy Intelligence |
P Protenus |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both grade A on AI centrality, and the split is method against scope. The methods differ at the root, which drives the governance grades: Imprivata EXPLAINS accesses, matching each against a legitimate reason and flagging only the unexplained residue, so it does not profile individuals and grades A on governance; Protenus PROFILES behaviour, building profiles of patients and users and reasoning about appropriateness, an approach graded C on governance because it flags named clinicians with no published fairness evaluation. Protenus answers a need Imprivata does not, covering diversion as well as privacy from one platform, with Best in KLAS in both. Imprivata carries the stronger evidence and transparency on its single domain, graded A on both, but its peer reviewed record and its in customer deployment model largely predate the FairWarning and Maize merger into Patient Privacy Intelligence, so buyers should confirm which capabilities carried over. Both are consequential workforce surveillance tools. Neither publishes a security attestation or pricing.